Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Jefferies Financial
JEF
5
Amazon
AMZN
US Stock MarketDetailed Quotes
ABVX Abivax S.A.
- 7.260
- +0.420+6.14%
Close Apr 28 16:00 ET
460.16MMarket Cap-2.27P/E (TTM)
7.410High6.948Low45.62KVolume7.095Open6.840Pre Close325.94KTurnover0.14%Turnover RatioLossP/E (Static)63.38MShares15.06052wk High9.93P/B232.37MFloat Cap4.77052wk Low--Dividend TTM32.01MShs Float17.020Historical High--Div YieldTTM6.76%Amplitude4.770Historical Low7.144Avg Price1Lot Size
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Abivax S.A. Stock Forum
Abivax Financial Results: EUR 144M War Chest Powers Pivotal UC Drug Trial
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
Abivax (ABVX) has reached a significant milestone in its Phase 3 ABTECT trial for obefazimod, enrolling 1,003 out of 1,224 targeted participants (82%) for treating moderately to severely active ulcerative colitis. The company expects to complete enrollment in Q2 2025, with top-line results for the 8-week induction trial anticipated in Q3 2025.
The 44-week maintenance data is expected in Q2 2026, followed ...
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
Abivax has announced initial preclinical combination data of obefazimod and etrasimod in an inflammatory bowel disease (IBD) mouse model. The company is conducting studies with multiple oral and injectable therapies, with additional data expected in Q4 2024. The p...
No comment yet